{"id":"W4392634581","doi":"10.1136/ijgc-2024-esgo.53","title":"285 Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Population; Internal medicine; Quality of life (healthcare); Clinical endpoint; Tolerability; Randomized controlled trial; Physical therapy; Adverse effect; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002257135,0.00145213,0.002660612,0.0004480168,0.0005036226,0.0008023545,0.0006654632,0.00134259,0.006514128],"category_scores_gemma":[0.00221498,0.0005198355,0.003669961,0.0004235242,0.0007165785,0.0008249375,0.0003325719,0.00287692,0.0007546577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007446329,"about_ca_system_score_gemma":0.0009118054,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001457482,"about_ca_topic_score_gemma":0.003020652,"domain_scores_codex":[0.9991195,0.0004613862,0.00008571124,0.0001326105,0.00009668671,0.0001040558],"domain_scores_gemma":[0.9987606,0.0005351208,0.0003285774,0.00008193295,0.00009906024,0.0001946747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9549673,0.005164023,0.001367415,0.002692513,0.006402279,0.00004216336,0.0000528545,0.0007240421,0.003541983,0.0001061133,0.001521193,0.02341826],"study_design_scores_gemma":[0.9232587,0.05914742,0.01021772,0.0001123759,0.004803081,0.00004945481,0.00003212545,0.0004856547,0.0006807318,0.0001473757,0.001036335,0.00002908105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9602571,0.02042328,0.001481652,0.0007799402,0.0005767613,0.00419491,0.006394132,0.0001863046,0.005706043],"genre_scores_gemma":[0.986012,0.004837847,0.001126149,0.0009745165,0.000328617,0.00188227,0.002892976,0.00002318105,0.001922364],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006514128,"threshold_uncertainty_score":0.02179193,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02594423331852203,"score_gpt":0.3469784173388849,"score_spread":0.3210341840203629,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}